[go: up one dir, main page]

WO2004011486A3 - Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse - Google Patents

Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse Download PDF

Info

Publication number
WO2004011486A3
WO2004011486A3 PCT/FR2003/002353 FR0302353W WO2004011486A3 WO 2004011486 A3 WO2004011486 A3 WO 2004011486A3 FR 0302353 W FR0302353 W FR 0302353W WO 2004011486 A3 WO2004011486 A3 WO 2004011486A3
Authority
WO
WIPO (PCT)
Prior art keywords
infectious
antitumoral
inducing
concerns
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/002353
Other languages
English (en)
Other versions
WO2004011486A8 (fr
WO2004011486A2 (fr
Inventor
Alain Beck
Nathalie Corvaia
Christine Klinguer-Hamour
Liliane Goetsch
Jean-Francois Haeuw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0209526A external-priority patent/FR2842812A1/fr
Priority claimed from FR0209522A external-priority patent/FR2842811A1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to AU2003273472A priority Critical patent/AU2003273472A1/en
Publication of WO2004011486A2 publication Critical patent/WO2004011486A2/fr
Publication of WO2004011486A3 publication Critical patent/WO2004011486A3/fr
Anticipated expiration legal-status Critical
Publication of WO2004011486A8 publication Critical patent/WO2004011486A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/02—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention a pour objet une molécule d'intérêt pharmaceutique, de préférence un ligand du Complexe Majeur d'Histocompatibité (CMH) hydrophobe soluble dans des solvants tels que le DMSO, rendu soluble dans un milieu aqueux injectable à l'Homme pour la préparation d'une composition pharmaceutique destinée à générer une réponse immunitaire médiée par des lymphocytes T cytotoxiques. L'invention concerne également l'utilisation de tels peptides mélangés ou couplés à une protéine porteuse pour la préparation d'une composition vaccinale destinée à la prévention de maladie infectieuses ou le traitement des cancers. L'invention a également pour objet de tels peptides, notamment à titre de médicament anti-infectieux ou antitumoral.
PCT/FR2003/002353 2002-07-26 2003-07-25 Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse Ceased WO2004011486A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003273472A AU2003273472A1 (en) 2002-07-26 2003-07-25 Method for solubilizing hydrophobic peptides and use thereof for inducing an antitumoral and/or anti-infectious ctl response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0209526A FR2842812A1 (fr) 2002-07-26 2002-07-26 Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
FR0209522A FR2842811A1 (fr) 2002-07-26 2002-07-26 Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
FR02/09526 2002-07-26
FR02/09522 2002-07-26

Publications (3)

Publication Number Publication Date
WO2004011486A2 WO2004011486A2 (fr) 2004-02-05
WO2004011486A3 true WO2004011486A3 (fr) 2004-04-15
WO2004011486A8 WO2004011486A8 (fr) 2005-04-28

Family

ID=31189579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002353 Ceased WO2004011486A2 (fr) 2002-07-26 2003-07-25 Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse

Country Status (2)

Country Link
AU (1) AU2003273472A1 (fr)
WO (1) WO2004011486A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6710157B2 (ja) * 2013-06-04 2020-06-17 トリビオティカ・エルエルシー 核酸に特異的なヘテロ化合物のテンプレート化アセンブリのための方法及び組成物
WO2016089958A1 (fr) 2014-12-02 2016-06-09 Tribiotica Llc Procédés et kits pour des applications théranostiques
EP3541940A4 (fr) 2016-11-21 2020-10-14 Tribiotica Llc Procédés d'assemblage par repliement dirigé ou de dimérisation de protéines par des réactions d'assemblage à matrice
US11186839B2 (en) 2016-11-21 2021-11-30 Tribiotica Llc Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789588A1 (fr) * 1999-02-17 2000-08-18 Pf Medicament Utilisation d'une proteine ompa d'enterobacterie associee a un antigene dans une composition pharmaceutique destinee a generer ou accroitre une reponse cytotoxique antivirale, antiparasitaire ou antitumorale

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789588A1 (fr) * 1999-02-17 2000-08-18 Pf Medicament Utilisation d'une proteine ompa d'enterobacterie associee a un antigene dans une composition pharmaceutique destinee a generer ou accroitre une reponse cytotoxique antivirale, antiparasitaire ou antitumorale

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BEDNAREK M A ET AL: "SOLUBLE HLA-A2.1 RESTRICTED PEPTIDES THAT ARE RECOGNIZED BY INFLUENZA VIRUS SPECIFIC CYTOTOXIC T LYMPHOCYTES", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 139, no. 1, 1991, pages 41 - 48, XP009008056, ISSN: 0022-1759 *
HORVATH A ET AL: "HEMAGGLUTININ-BASED MULTIPEPTIDE CONSTRUCT ELICITS ENHANCED PROTECTIVE IMMUNE RESPONSE IN MICE AGAINST INFLUENZA A VIRUS INFECTION", IMMUNOLOGY LETTERS, AMSTERDAM, NL, vol. 60, no. 2/3, February 1998 (1998-02-01), pages 127 - 136, XP000917227, ISSN: 0165-2478 *
JAEGER ELKE ET AL: "Clonal expansion of Melan a-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.", INTERNATIONAL JOURNAL OF CANCER, vol. 86, no. 4, 15 May 2000 (2000-05-15), pages 538 - 547, XP002235374, ISSN: 0020-7136 *
MATSUSHITA SHO ET AL: "The N-terminal six residues of peptide core sequences suffice for binding to HLA-DR4 (DRB1*405) and DR9 (DRB1*0901) molecules.", IMMUNOLOGY LETTERS, vol. 58, no. 2, 1997, pages 89 - 93, XP002235372, ISSN: 0165-2478 *
SPOUGE J L ET AL: "STRONG CONFORMATIONAL PROPENSITIES ENHANCE T CELL ANTIGENICITY", JOURNAL OF IMMUNOLOGY, vol. 138, no. 1, 1987, pages 204 - 212, XP009008085, ISSN: 0022-1767 *
WANG F ET AL: "Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES OCT 1999, vol. 5, no. 10, October 1999 (1999-10-01), pages 2756 - 2765, XP002235373, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
AU2003273472A8 (en) 2004-02-16
WO2004011486A8 (fr) 2005-04-28
WO2004011486A2 (fr) 2004-02-05
AU2003273472A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
WO2005049073A3 (fr) Proteines appartenant a la famille bcl-2, fragments associes, et utilisation therapeutique de ces proteines et fragments sur des patients atteints du cancer
GB2374010B (en) Novel vitamin B12 - biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
EP2325205A3 (fr) Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
DE50000639D1 (de) Verfahren zur stabilisierung von polyvinylpyrrolidon-zubereitungen
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
EP2322217A3 (fr) Traitement combiné pour malignités non hematologiques par anticorps anti-IGF-1R
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
WO2004067023A3 (fr) Peptides derives de la survivine et leur utilisation
MXPA05002814A (es) Formulacion para agentes lipofilicos.
HK1042234A1 (zh) 向肺部施加乾粉配方以治疗不育症
WO2002098360A3 (fr) Compositions a base de proteines du stress et methodes de prevention et de traitement d'un cancer ou d'une maladie infectieuse
WO2015140175A9 (fr) Médicament destiné à être utilisé dans un procédé d'induction ou d'extension d'une réponse immunocytotoxique cellulaire
WO2004060317A3 (fr) Combinaison de composes a base de gallium et d'agents anticancereux non chimiotherapeutiques destinee au traitement de la neoplasie
WO2001070772A3 (fr) Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide
WO2005051902A8 (fr) Canal proteique mscl modifie
EP1958960A3 (fr) Processus pour la préparation d'un vaccin d'anthrax non toxique
WO2003033644A3 (fr) Peptide utile pour l'immunomodulation
WO2004011486A3 (fr) Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse
WO2002062833A3 (fr) Leptine modifiee ayant une immunogenicite reduite
WO2004069206A3 (fr) Complexes de molecule antigene-ligand immunogene cd91 et proteines de fusion
EP1801123A3 (fr) Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
WO2003093298A3 (fr) Peptides immunogenes
WO2000066173A3 (fr) Procedes et formulations pour cibler des agents infectieux supportant des proteines des cellules hotes
WO2004058807A3 (fr) Peptides de stimulation de lymphocytes t a restreint par des molecules de classe i provenant du virus de l'hepatite b
NO20023249D0 (no) Nye substituerte pyrazolo(4,3-e)ediazepiner, farmasöytiske preparater inneholdende disse, anvendelse som medisinske produkterog fremgangsmåter for fremstilling derav

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 06/2004 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP